Recently diagnosed with HIV? Click here

Rollover Tipranavir and Ritonavir Trial

Clinical trial • Reported • 28 March 2008
This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.

About this trial

This study is testing a combination of tipranavir and ritonavir to see how safe and easy-to-take the drugs are together.

The idea is to combine the two drugs into one pill or 'fixed dose combination' containing 500mg of tipranavir and 200mg of ritonavir which can be taken twice a day along with an optimized background regimen.

Background information

'Fixed-dose combinations' are popular because they can reduce 'pill burden' for the people taking them while increasing 'pill sales' for the companies selling them.

Other licensed fixed-dose combination pills include Combivir (lamivudine/zidovudine), Trizivir (abacavir/lamivudine/zidovudine) and Truvada (tenofovir/emtracitabine).

Official title:A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects
What is this trial studying?Treatment strategy
How many participants will this trial enrol?1074

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

How long is this trial planned to go for?Participants in this trial will be asked to follow the treatment strategy for 48 weeks. Following the conclusion of the trial, participants will be followed up for a further 48 weeks.
Links to further information:
Can I access this treatment other than by enrolling in this trial?

Both drugs are licensed under the s100 scheme in Australia

Tags:optimised background regimens

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • All subjects must have successfully completed participation in a combination tipranavir/ritonavir trial or have confirmed virologic failure in the RESIST trials

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 28 March 2008 — more than three years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more